# Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

> **NCT06062485** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 30 (estimated)

## Conditions studied

- Ampullary Carcinoma

## Interventions

- **DRUG:** Surufatinib+Toripalimab+AG

## Key facts

- **NCT ID:** NCT06062485
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10
- **Primary completion:** 2025-10
- **Final completion:** 2026-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062485, "Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06062485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*